(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.20%) $2 347.20
(-0.35%) $27.54
(0.17%) $922.10
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...
Stats | |
---|---|
Dagens volum | 39.49M |
Gjennomsnittsvolum | 52.37M |
Markedsverdi | 50.97B |
EPS | HKD0 ( 2024-03-29 ) |
Neste inntjeningsdato | ( HKD0 ) 2024-06-14 |
Last Dividend | HKD0.0600 ( 2023-06-20 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 25.18 |
ATR14 | HKD0.00800 (0.29%) |
Volum Korrelasjon
Sino Biopharmaceutical Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Sino Biopharmaceutical Korrelasjon - Valuta/Råvare
Sino Biopharmaceutical Økonomi
Annual | 2023 |
Omsetning: | HKD26.20B |
Bruttogevinst: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2023 |
Omsetning: | HKD26.20B |
Bruttogevinst: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2022 |
Omsetning: | HKD28.78B |
Bruttogevinst: | HKD22.98B (79.86 %) |
EPS: | HKD0.270 |
FY | 2021 |
Omsetning: | HKD26.86B |
Bruttogevinst: | HKD21.53B (80.15 %) |
EPS: | HKD0.780 |
Financial Reports:
No articles found.
Sino Biopharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00198 | 2004-09-16 |
Last Dividend | HKD0.0600 | 2023-06-20 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 70 | -- |
Total Paid Out | HKD0.573 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.91 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.14 | |
Div. Directional Score | 7.37 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9983.HK | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
2192.HK | Ex Dividend Junior | 2023-11-07 | Annually | 0 | 0.00% | |
1198.HK | No Dividend Player | 2023-07-21 | Sporadic | 0 | 0.00% | |
0270.HK | Ex Dividend Knight | 2023-10-06 | Semi-Annually | 0 | 0.00% | |
3908.HK | Ex Dividend Junior | 2023-07-04 | Sporadic | 0 | 0.00% | |
1772.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
0811.HK | Ex Dividend Knight | 2023-05-22 | Annually | 0 | 0.00% | |
2356.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1330.HK | Ex Dividend Junior | 2023-06-28 | Annually | 0 | 0.00% | |
0386.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0711 | 1.500 | 8.58 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0247 | 1.200 | 9.18 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0519 | 1.500 | -0.534 | -0.801 | [0.1 - 1] |
payoutRatioTTM | 0.404 | -1.000 | 5.96 | -5.96 | [0 - 1] |
currentRatioTTM | 1.053 | 0.800 | 9.73 | 7.79 | [1 - 3] |
quickRatioTTM | 0.755 | 0.800 | -0.263 | -0.210 | [0.8 - 2.5] |
cashRatioTTM | 0.418 | 1.500 | 8.79 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.197 | -1.500 | 6.72 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.410 | -1.500 | 8.36 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.788 | 1.000 | 0.197 | 0.197 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.203 | 1.000 | 7.94 | 7.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.306 | 1.000 | 9.41 | 9.41 | [0.2 - 2] |
assetTurnoverTTM | 0.347 | 0.800 | -1.020 | -0.816 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.82 | 1.000 | 6.89 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0519 | 2.50 | -0.343 | -0.801 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.404 | 1.500 | 5.96 | -5.96 | [0 - 1] |
pegRatioTTM | 0.329 | 1.500 | -1.141 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.174 | 1.000 | 8.16 | 0 | [0.1 - 0.5] |
Total Score | 5.14 |
Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.